As s tated previous ly, the dis eas e proces s of heart failure can be caus ed by multiple factors . There are three contributors to heart contractibility, thes e include preload, contractility, and afterload, which all impact s troke volume (Lekavich et al., 2015) . Preload is the volume of blood filling the ventricle before it contracts , where afterload is referred to as the pres s ure the ventricle has to work against when ejecting blood out of the ventricles generated by the pulmonary and systemic circulatory s ys tems (Cas ey, 2013, p. 22) . Preload is reflected by blood volume, therefore a change in levels alters preload and s troke volumes. Afterload increases with a rise in peripheral vascular res is tance, caus ing the ventricles to work harder than normal. Contractility is referred to as the heart mus cle's ability to eject the blood out of the ventricles (Cas ey, 2013, p. 22) . Contractility is mos t often altered as a res ult of damage after a heart attack. Contractility can als o be altered by changes in blood calcium level, a proces s that occurs with myocardial cell injury, which reduc es c ardiac output (Marín-García, 2016 ).
• For nurses taking care of patients with heart failure, it is important to cons ider all factors when addres s ing their care. The patient and family s hould mos t importantly be educated on the dis eas e its elf in order to improve s elfmanagement. Lifes tyle changes commonly recommended include s moking ces s ation, decreas ed alcohol cons umption, and increas e in exercis e (N ichols on, 2014). As noted by Cas ey (2013), emphas is was placed on the importance of diet modification including low s odium and fluid intake, in addition to clos e monitoring of daily weights (p. 23). A note should be given to care providers to address the topic of depres s ion s ince the prevalence among thos e diagnos ed with heart failure is high.
• Appropriate control of comorbidities such as diabetes , hypercholes terolemia and kidney dis eas e improves cardiac outcomes (N ichols on, 2014). Proper interventions s hould be adminis tered bas ed off of the patient's pres enting s igns and s ymptoms .
• The goal of treatment is to improve life expectancy and quality of life. Common pharmacological s trategies include the us e of angiotens in-converting enzyme (ACE) inhibitors , diuretics , and beta-adrenoceptor blockers (beta blockers ).
• ACE inhibitors are pres cribed to patients firs t in HFrEF due to their ability to hinder the productions of angiotens in II caus ing arteriole vasodilation (Lekavich et al., 2015) . Therefore, they reduce preload and afterload.
• Diuretics are recommended for all types of heart failure for their capability of reducing fluid retention and overload, therefore relieving the patient's s ymptoms of heart failure (Reddy & Borlaug, 2016) . As a res ult of exces s fluid being excreted, preload is reduced.
• Beta blockers are typically given in addition to ACE inhibitors due to their ability to decreas e the heart rate and therefore prolong dias tole and improve ventricular filling (Reddy & Borlaug, 2016 ).
• As a nurs e in the Emergency Department at Mount Carmel W es t, many patients come in exhibiting s igns and s ymptoms of heart failure. Not every patient dis plays the s ame s ymptoms and not all patients are on the s ame treatment regimen. It is beneficial for nurs es taking care of thes e patients to be knowledgeable on the disease process and what symptoms patients can experience.
• Heart failure can be defined as the inability of the heart to pump effectively enough to meet metabolic demands of the body's tis s ues (Lodge & Yous ef, 2016, p. S12). This could be caus ed by damage to cardiac tis s ue or as a res ult of dis eas e proces s (Cas ey, 2013, p. 20) . Many patients have multiple medic al c onditions that can contribute to heart failure. As a res ult, compensatory mechanisms may be initiated to counteract the side effects of the disease causing systemic changes.
• The prevalence of this dis eas e is very high in the U nited States , and it is going to continue to ris e. According to Reddy & Borlaug (2016) , it is expected that approximately 8 million adults in the U nited States will have heart failure in 2030. Prognosis is often poor and quality of life for patients is diminis hed, caus ing s tres s and hards hip for patients and their family members . Roughly half of the people who develop heart failure die within five years of diagnos is (Brias oulis , Androulakis , Chris tophides , & Tous oulis , 2016).
• With s uch a wides pread dis eas e, it is vital that healthcare providers become familiar with dis eas e pres entation, contributing factors , and treatment options . According to Reddy & Borlaug (2016) , the cost of healthcare for heart failure was estimated to be $21 billion in 2012. Cons equently, it is important for an advanced practice nurs e frequently encountering thes e patients to unders tand the pathophys iology behind the dis eas e proces s to determine the proper choice of treatment to help further reduce cos t.
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Heart failure is a c ommon dis eas e that exis ts always in the pres ence of other ailments . The detriment of the illnes s can be monumental for patients and families . W ith the improvement of health care quality, the occurrence is expected to increas e. Knowing the pathophys iology allows the caregiver to appropriately determine what treatment is the bes t choice for that patient. The choice of treatment should always be specific to the patient bas ed off of their current dis eas e proces s and include the patient's wis hes . Successful management can result in decrease hos pital admis s ions and improved quality of life.
Conclusion Risk Factors
• Common caus es of heart failure are is chemic heart dis eas e, myocardial infarction, hypertens ion, and arrhythmias (N ichols on, 2014). Other caus es include cardiomyopathies , myocarditis , valve dis orders , amyloidos is , s arcoidos is , and exces s ive alcohol us e (N ichols on, 2014).
• Ris k factors for dias tolic heart failure are well es tablis hed and include hypertens ion, older age (es pecially in women), kidney dis eas e, anemia, diabetes , coronary artery dis eas e, s edentary lifes tyle, and obes ity (Reddy & Borlaug, 2016) . Komomura (2013) points out the s ignificant finding of a high comorbidity rate of obes ity, diabetes , and chronic kidney dis eas e with dias tolic heart failure, therefore emphas iz ing the importance of patient education and lifes tyle modification.
• The greates t ris k factors for s ys tolic heart failure are myocardial infarction and hypertens ion (Reddy & Borlaug, 2016) . Hypertens ion increas es peripheral vas cular res is tance, therefore caus ing the left ventricle to work harder, dilate, and have decreas ed contractility.
• Right sided heart failure is commonly associated with pulmonary disease when not related to left ventricular dysfunction. Chronic obstructive pulmonary disease (COPD) causes resistance against the right ventricle when pumping blood into the pulmonary circulation, bringing about damage.
Significance of Pathophysiology
Understanding the pathophys iology allows caregivers to determine what type of heart failure the patient has and what s igns and s ymptoms to expect. This information als o provides the caregiver with knowledge of other diseases the patient is at risk for and what illnesses may have contributed to the patient's heart failure. It is vital for the provider to unders tand all factors and manifes tations the patient has in order to properly identify the patient's ability for treatment and recovery. There are s everal different types of heart failure. Thes e include left ventricular failure (s ys tolic and dias tolic heart failure) and right ventricular failure.
Systolic Heart Failure
Systolic heart failure is the inability of the left ventricle to contract effectively causing reduced blood circulation to the body (Cas ey, 2013, p. 21). Often, it is referred to as heart failure with reduc ed ejec tion frac tion (HFrEF). Ejection fraction is s imply the percentage of blood coming out of the left ventricle with each contraction. Diagnos is of HFrEF is an ejection fraction <40% with a normal being >50% (Reddy & Borlaug, 2016) . The dis tinguis hing factors in s ys tolic heart failure is ventricular dilatation and markedly depres s ed contractility (Reddy & Borlaug, 2016) . The chief outcomes of HFrEF are pulmonary congestion due to increase in atrial pressure and poor circulation due to decreas ed cardiac output.
RAAS
When the heart is unable to effectively function as a pump the renin-angiotens in-aldos terone s ys tem (RAAS) is activated. Dec reas ed blood flow due to poor c ardiac output s timulates the kidneys to releas e renin, which turns angiotens inogen into angiotens in II (Lodge & Yous ef, 2016, p. S13). Angiotens in II has detrimental effects to cardiac tis s ue. W hen there are cons is tent elevated levels of Aldos terone II, vas ocons triction occurs causing an increase in blood pressure and myocyte hypertrophy (Lodge & Yous ef, 2016, p. S14). The synthesis of aldosterone is stimulated by angiotensin II (Sousa-Pinto, Ferreira-Pinto, Santos , & Leite-Moreira, 2014). Aldos terone is a hormone that caus es s odium and water retention, which increas es blood volume, and cardiac output (Lodge & Yous ef, 2016, p. S14). Increas ed blood volume due to aldosterone and vasoconstriction from angiotens in II, caus es further myocyte damage and fibros is occurs . Another hormone that retains water and caus es vasoconstriction is arginine vasopressin (antidiuretic hormone [ADH] ). ADH is releas ed as a res ult of atrial s tretching and a decreas e in cardiac output (Lodge & Yous ef, 2016, p. S14) . Overs tretching as a res ult of increas ed volume, therefore increas ed preload, decreas es cardiac output. Afterload is increas ed due to vas ocons triction and water retention, caus ing the heart to increas e workload res ulting in an increas e in metabolic demands . W hen the myocytes are unable to keep up with demands , hypertrophy and remodeling occurs . This perpetuates the cycle of heart failure.
SNS
When there is a decreas e in blood pres s ure and cardiac output, the s ympathetic nervous s ys tem (SN S) is activated. Stimulation of the s ympathetic nervous s ys tem generates the releas e of noradrenaline (norepinephrine), which triggers beta-rec eptors to increas e heart rate, s trength and s peed of contractions (Cas ey, 2013, p. 22) . As a res ult of increas ed heart rate, the ventricles begin to thicken (hypertrophy) and collagen depos ition occurs , caus ing dys function, this is called remodeling (Anders en, Anders en, de Man, & N iels en-Kuds k, 2015) . Ventricular hypertrophy has a s ignificantly negative effect on the heart's contractility. Mec hanic al s timulation to the myocardium is the main factor of myocardial hypertrophy, whereas myocardial fibros is may be caus ed by neurohumoral compensatory mechanisms such as cytokines and hormones (Komamura, 2013) . Overtime, this compens atory mechanis m can become toxic to the heart cells , therefore rendering the cells unable to res pond to the body's attempts to compens ate.
Signs and Symptoms Left Heart Failure versus Right Heart Failure
Left heart failure is commonly called congestive heart failure (CHF). It can be further categorized by systolic heart failure or diastolic heart failure based off of ejection fraction. Left heart failure is essentially the incapability of the heart to perfus e the body's vital organs . Right heart failure is the inability of the heart to adequately perfus e the pulmonary circulation. Right heart failure is caus ed by increas ed res is tance of the pulmonary circulation, caus ing the right ventricle to fail. Left heart failure is correlated with pulmonary edema whereas right heart failure is connected to peripheral and vis ceral edema (Cas ey, 2013, p. 21) . Mos t often, right heart failure occurs as a res ult of left s ided heart failure.
Diastolic Heart Failure
Dias tolic heart failure is referred to as heart failure with pres erved ejection fraction (HFpEF). Dias tolic heart failure is when a normal ejection fraction occurs with impaired left ventricular relaxation. Typically, diagnos is of HFpEF is an ejection fraction of >50%, which is normal (Lekavich et al., 2015) . Myoc ardial fibros is or hypertrophy oc c ur often as a res ult of hypertens ion, ending in increas ed left ventricular stiffness with decreased filling ability (Komamura, 2013) . The left ventricle is not filling enough in dias tole, s o to compens ate, preload is increas ed, which in turn increas es left atrial pres s ure and as a res ult, directly caus es pulmonary congestion (Komamura, 2013) .
Remodeling
According to Marín-García (2016), "three major cell death modalities , apoptos is , necros is and autophagy, occur in cardiomyocytes , and both gradual and acute cell death are features of the cardiac pathophys iology, including is chemia, myocardial infarction, and progres s ive heart failure" (p. 1). Inflammation is important to repair damaged tis s ue, but over activation can caus e extens ive des truction. As a res ult of prolonged inflammation, es pecially in later s tages of heart failure, hypertrophy, fibros is , and cell death occur in cardiac tis s ue, which is known as remodeling (Brias oulis , Androulakis , Chris tophides , & Tous oulis , 2016). Damaged myocardium produces reactive oxygen s pecies (ROS) which caus es s tres s , inflammation, and cell death, res ulting in the releas e of proinflammatory cytokines interleukin -1 (IL-1) and TN F-α (Sous aPinto, Ferreira-Pinto, Santos , & Leite-Moreira, 2014) . Thes e molecules exacerbate heart failure by increas ing leukocyte attraction, proliferating the inflammatory res pons e, and increas ing endothelial des truction. Endothelial des truction causes a reduced production of nitric oxide (a known vasodilator) therefore resulting in vasoconstriction (Brias oulis , Androulakis , Chris tophides , & Tous oulis , 2016). Vas ocons triction continues to s timulate the neurohumoral and inflammatory res pons e, therefore proliferating the cycle of damage.
